Détails de l'événement
The Clinical Trials on Alzheimer’s Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease.
This year the 14th annual CTAD conference will be in Boston on November 9-12, 2021. Our new innovative format will combine an onsite meeting in Boston with on-demand scientific content on a digital platform.
CTAD’s prime mission is to inform and educate on the latest in AD therapeutic trials. Therefore, the entire cutting-edge scientific program will be fully available on demand on our digital platform for those who cannot attend in person in Boston for economic or travel reasons.
As such, onsite in Boston, the scientific program will feature the best presentations in the ballroom, leaving dedicated times for discussion and networking opportunities for delegates and partners.
Participants will be able to access additional content on demand on the digital platform.
CTAD 2021 combines the best of both options, participants will discover the latest updates in AD clinical research while enjoying the many networking opportunities CTAD has to offer in Boston.
Looking forward to seeing you in Boston!
On behalf of the Organizing Committee.
Jacques Touchon, MD, PhD, University of Montpellier, France
Paul Aisen, MD, Alzheimer’s Therapeutic Research Institute (ATRI) at the University of Southern California (USC) at San Diego
Bruno Vellas, MD, PhD, University Hospital of Toulouse, France
Mike Weiner, MD, University of California San Francisco (UCSF), USA
For more informations, visit the CTAD website : https://www.ctad-alzheimer.com/